Yellow Jack is an old sailor and military term for yellow fever, a viral illness transmitted by mosquitoes that remains one of the most dangerous infectious diseases in tropical regions of Africa and South America. The virus attacks the liver, which causes the jaundice that gives the disease its name, and severe cases can progress to organ failure, hemorrhage, and death. Despite the existence of a highly effective vaccine for nearly a century, yellow fever still kills tens of thousands of people each year, and the disease has no approved antiviral treatment. Understanding its symptoms, the current state of treatment, and how to prevent infection matters for anyone living in or traveling to endemic areas.
Why It Was Called Yellow Jack
The nickname dates to the era of Atlantic sailing ships. Vessels carrying crew members sick with yellow fever were required to fly a yellow quarantine flag, and the disease became synonymous with that signal. Sailors and soldiers in the Caribbean and Gulf Coast dreaded “Yellow Jack” as one of the deadliest threats they could encounter, a disease far more lethal than many other epidemics of the era.1OAH Magazine of History. Yellow Jack and Geopolitics: Environment, Epidemics, and the Struggles for Empire in the American Tropics, 1650–1825 Yellow fever shaped geopolitics for centuries, spreading along Atlantic slave trade routes and devastating colonial armies. Epidemics influenced the outcomes of wars and the fates of empires.2PubMed. Yellow Fever: A Perennial Threat The mystery of how the disease spread was not solved until 1881, when Cuban physician Carlos Finlay proposed that mosquitoes were the vector. His theory was later confirmed by the U.S. Army Yellow Fever Commission, led by Walter Reed, using human volunteers.3PubMed. Carlos Finlay and yellow fever: triumph over adversity
How Symptoms Unfold in Two Phases
Most people bitten by an infected mosquito never realize they have yellow fever. The majority of infections cause no symptoms at all. Among those who do get sick, the illness typically unfolds in two distinct phases, though many people recover after the first and never experience the second.
The initial phase, sometimes called the viremic phase, begins three to six days after a mosquito bite. It brings on sudden high fever, muscle pain (particularly in the back), headache, loss of appetite, and nausea. This stage usually lasts about three days and then subsides. Mild and moderate cases, estimated to account for roughly 20 to 30 percent of those who develop symptoms, end here with full recovery.4Rev. Assoc. Med. Bras.. Open-access Yellow fever – Section: Clinical manifestation
The dangerous turn happens in roughly 15 percent of symptomatic patients. After a brief period of apparent improvement lasting about a day, the fever surges back, headache and body pain worsen, and the disease enters its toxic phase.4Rev. Assoc. Med. Bras.. Open-access Yellow fever – Section: Clinical manifestation This is when the classic and most feared signs appear: jaundice (the yellowing of skin and eyes), dark or bloody vomit, bleeding from the gums or nose, and reduced urine output. A characteristic clinical sign is Faget’s sign, where the heart rate drops even as the fever stays high, a peculiar mismatch between pulse and temperature that clinicians use as a diagnostic clue.5Journal of Brazilian Pathology and Laboratory Medicine. Yellow fever: laboratorial diagnosis and clinical manifestations – Section: Clinical Manifestations
What the Virus Does to the Liver and Blood
The jaundice that defines yellow fever reflects severe liver damage. The yellow fever virus has a particular affinity for liver cells, and studies of fatal cases show a distinctive pattern of injury concentrated in the middle zone of the liver lobule. Rather than widespread inflammatory destruction, the primary mode of liver cell death is apoptosis, a form of programmed cell death, with relatively little surrounding inflammation given how much tissue is damaged.6PubMed. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity Dead liver cells form distinctive round, densely packed structures called Councilman bodies, which pathologists have long considered a hallmark of yellow fever on biopsy.7PubMed. Histopathology of the human liver in yellow fever with special emphasis on the diagnostic role of the Councilman body
The bleeding that occurs in severe cases involves more than just the liver failing to produce clotting factors. Research shows that patients develop what is called consumptive coagulopathy, where the clotting system becomes overactivated and uses up its own components faster than the body can replace them. Elevated levels of D-dimer, a breakdown product of blood clots, have been found in the blood of patients with severe yellow fever, confirming this process is underway.8PubMed Central. Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury Intriguingly, animal model research suggests that the bleeding disorder does not come solely from liver cell infection. When mice with humanized livers were infected, they developed liver damage but not the full consumptive coagulopathy seen in primates, indicating that infection of other cell types throughout the body contributes to the hemorrhagic syndrome.8PubMed Central. Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury
A viral protein called NS1 also plays a role in making blood vessels leak. In patients with severe yellow fever, NS1 levels in the blood are significantly elevated and correlate with markers of vascular damage and disease severity. NS1 appears to strip protective molecules from the surface of cells lining blood vessels, increasing permeability and contributing to the shock and fluid loss that can be fatal.9EBioMedicine. Endothelial dysfunction and viral non-structural protein 1 in human yellow fever – Section: Results
Diagnosing Yellow Fever
The early symptoms of yellow fever, including fever, headache, and muscle pain, overlap heavily with dozens of other tropical infections. Dengue, Zika, malaria, leptospirosis, and rickettsial diseases can all look similar in the first few days. In a study of fatal febrile illness cases in Colombia that were initially suspected to be leptospirosis, investigators later identified a range of other causes including dengue, Zika, Rickettsia, and yellow fever.10PLOS Neglected Tropical Diseases. Fatal acute undifferentiated febrile illness among clinically suspected leptospirosis cases in Colombia, 2016–2019 – Section: Results This diagnostic overlap means laboratory confirmation is essential.
Confirming yellow fever requires either detecting the virus’s genetic material in blood (using RT-PCR, which works best during the first few days of illness) or finding antibodies produced in response to the virus (using serological tests, which become reliable later in the course). Both approaches have their limitations. An international quality assessment of laboratories performing yellow fever diagnosis found that both molecular and serological techniques needed improvement, highlighting that even well-equipped labs can struggle with accuracy.11PLoS ONE. First International External Quality Assessment Study on Molecular and Serological Methods for Yellow Fever Diagnosis Serological tests are further complicated by cross-reactivity with other closely related viruses like dengue and Zika, which can produce false positives.
Treatment Is Supportive, but Intensive Care Can Save Lives
There is no approved antiviral drug for yellow fever. Treatment centers on managing symptoms and supporting organ function while the body fights the virus. For mild cases, rest, fluids, and fever management are enough. For severe cases, the picture is entirely different, and outcomes depend heavily on the intensity and quality of critical care available.
A 2025 Colombian expert consensus established detailed guidelines for managing critically ill yellow fever patients. The recommendations emphasize early admission to intensive care when there are signs of liver dysfunction, kidney failure, or shock. Fluid resuscitation needs to be carefully individualized to avoid overloading the circulation, and blood pressure support with norepinephrine should not be delayed when low blood pressure persists. Platelet transfusions are restricted to specific situations, and intra-abdominal pressure requires close monitoring. For the most severe cases, the consensus recommends plasma exchange and kidney replacement therapy.12PubMed Central. Colombian consensus on the care of critically ill patients with suspected or confirmed severe yellow fever
Plasma exchange, a procedure that removes the patient’s blood plasma and replaces it with donor plasma, has shown striking results in one case series. In a study comparing three groups of severe yellow fever patients, those who received standard intensive care alone had a mortality rate of about 85 percent. A high-volume plasma exchange protocol did not improve on that. But an intensive plasma exchange regimen, performed twice daily with fresh frozen plasma, dropped mortality to 14 percent and was associated with faster clearance of the virus from the blood.13PubMed Central. Intensive Therapeutic Plasma Exchange-New Approach to Treat and Rescue Patients with Severe Form of Yellow Fever This is a single observational study with a small number of patients, not a randomized controlled trial, so the results need to be interpreted cautiously. But in a disease where severe cases have historically killed the large majority of those affected, the signal is hard to ignore.
Monoclonal Antibodies on the Horizon
The most promising development in yellow fever treatment may be monoclonal antibodies, lab-made proteins designed to neutralize the virus directly. Researchers screened dozens of antibodies isolated from people who had been vaccinated against yellow fever and identified candidates capable of neutralizing multiple strains of the wild virus. In animal models of lethal yellow fever, a single dose of these antibodies during acute infection completely controlled the virus in the blood and prevented death.14PubMed Central. Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection
Follow-up work tested one of these antibodies (called MBL-YFV-01) at a lower, more practical dose in rhesus macaques and confirmed its effectiveness both as prevention and as treatment. When given before infection, the antibody protected all animals. When given three and a half days after infection, a time point at which the virus is already actively replicating, three out of four treated animals survived, compared to none of the untreated animals.15PubMed Central. Prophylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection – Section: Results These antibodies have not yet been tested in human clinical trials, but they represent the first realistic prospect of a targeted treatment for severe yellow fever.
Vaccination Remains the Best Defense
The yellow fever vaccine, based on a weakened live virus strain called 17D developed in the 1930s, is one of the most effective vaccines ever created. A single dose triggers strong immune responses, and the protection appears to be remarkably durable. One study found that people still had functional memory immune cells 18 years after vaccination and protective levels of neutralizing antibodies 35 to 40 years after a single dose, supporting the conclusion that one vaccination can provide lifelong immunity.16PLoS ONE. A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination – Section: Results This is why the World Health Organization removed its previous recommendation for booster doses every ten years, now stating that a single dose provides lifetime protection for most people.
Vaccination is required for entry into many countries in Africa and South America and recommended for all travelers to endemic areas. The vaccine is widely available through travel clinics and public health programs. For residents of endemic countries, routine childhood immunization programs are the backbone of prevention.
When Vaccine Supplies Run Short
One of the ongoing challenges with yellow fever prevention is that global vaccine supply cannot always keep up with demand, especially during large outbreaks. In response, researchers have tested whether smaller, fractional doses of the vaccine can still protect people. During an outbreak in Brazil, a fractional dose of the 17DD vaccine was effective at triggering protective antibody responses in people who had no prior immunity. Nearly all participants who developed antibodies at one month after vaccination maintained protective levels at one year.17PubMed Central. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak – Final Report
A separate randomized trial tested one-fifth doses of all four WHO-prequalified yellow fever vaccines and found that these fractional doses were effective across the board. The practical implication is significant: fractional dosing could expand the available outbreak stockpile by up to five times, turning existing supplies into a much larger shield during emergencies.18The Lancet. Immunogenicity and safety of one-fifth fractional doses of yellow fever vaccines (FAViCoV): a double-blind, randomised, controlled, non-inferiority trial – Section: Interpretation This strategy has already been deployed in real-world outbreak responses and is now part of WHO policy.
Rare but Serious Vaccine Reactions
Because the yellow fever vaccine contains a live, weakened virus, it carries a small risk of serious adverse events that other vaccine types do not. The most concerning is vaccine-associated viscerotropic disease, in which the weakened vaccine virus behaves more like the wild virus and causes systemic illness resembling yellow fever itself. This complication is rare but can be fatal. A review found that all serious adverse events meeting standardized classification criteria were associated with first-time yellow fever vaccinations, not boosters.19PubMed Central. Yellow fever vaccine-associated viscerotropic disease: current perspectives
Who is at higher risk for these rare reactions? Age is one factor: people over 60 receiving their first dose appear to face a somewhat elevated risk. People with compromised immune systems, including those with HIV, organ transplants, or autoimmune conditions requiring immunosuppressive drugs, are generally advised against receiving the vaccine. Genetic factors may also play a role. In one documented case of vaccine-associated viscerotropic disease, the patient was found to carry genetic variants in immune signaling genes (CCR5 and RANTES) that may have impaired the body’s ability to direct immune cells to infected tissues and control the vaccine virus.20PubMed Central. Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and polymorphisms in CCR5 and RANTES Genes – Section: Genetic Analyses The significance of these genetic findings is still uncertain, but they illustrate that individual biology can influence how a person responds to the vaccine.
Mosquito Control and Environmental Factors
Vaccination protects individuals, but preventing outbreaks also requires reducing contact between people and infected mosquitoes. In cities, the primary vector is Aedes aegypti, the same mosquito species responsible for dengue, Zika, and chikungunya. In forested areas of South America, a different group of mosquitoes (primarily Haemagogus species) maintains the virus in a cycle between monkeys and mosquitoes, with humans getting infected when they enter or live near these forests.
Traditional mosquito control methods like insecticide spraying and eliminating standing water breeding sites remain important. A newer approach uses genetically engineered male mosquitoes carrying a self-limiting gene. When these modified males mate with wild females, over 95 percent of their offspring die before reaching adulthood. In an outdoor containment trial in India, releases of these self-limiting Aedes aegypti males successfully suppressed a wild mosquito population.21PLOS Neglected Tropical Diseases. Elimination of a closed population of the yellow fever mosquito, Aedes aegypti, through releases of self-limiting male mosquitoes
Climate change adds another layer of complexity to yellow fever risk. A modeling study that examined Brazil’s 2017-2018 outbreak projected how changing temperatures might affect future outbreaks. Under higher-emission scenarios, rising temperatures could actually reduce the suitability of some regions for the Haemagogus mosquitoes that drive sylvatic (forest-cycle) transmission, potentially shortening outbreak duration and lowering peak case counts in certain areas.22ScienceDirect (Infectious Disease Modelling). Yellow fever virus outbreak in Brazil under current and future climate – Section: Results That finding might sound counterintuitively reassuring, but it does not account for potential range shifts where mosquitoes move into newly suitable areas, or for the urban Aedes aegypti cycle, which involves a different and highly adaptable vector. The overall picture is one of shifting rather than simply shrinking risk.
The Virus Itself
Yellow fever virus belongs to the flavivirus family, a group that also includes dengue, Zika, and West Nile viruses. Its genome is a single strand of RNA roughly 10,000 nucleotides long, encoding one large protein that gets chopped into individual functional pieces after it is made. The structural proteins that form the virus particle sit at one end of this sequence, while the rest encodes the molecular machinery the virus uses to copy itself inside a host cell.23PubMed. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution This close relationship with other flaviviruses is what makes serological diagnosis so tricky: antibodies produced against dengue or Zika can cross-react with yellow fever tests and vice versa, a practical headache in regions where multiple flaviviruses circulate simultaneously. For travelers, the family resemblance also means that previous dengue or Zika infections do not protect against yellow fever. Only the yellow fever vaccine, or recovery from yellow fever itself, provides reliable immunity against the disease that sailors once feared above almost everything else the tropics could throw at them.